LifeTech Scientific Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

LifeTech Scientific heeft een totaal eigen vermogen van CN¥3.4B en een totale schuld van CN¥99.0M, wat de schuld-eigenvermogensverhouding op 2.9% brengt. De totale activa en totale passiva bedragen respectievelijk CN¥4.8B en CN¥1.4B. De EBIT LifeTech Scientific is CN¥262.5M waardoor de rentedekking -16 is. Het heeft contanten en kortetermijnbeleggingen van CN¥1.0B.

Belangrijke informatie

2.9%

Verhouding schuld/eigen vermogen

CN¥99.00m

Schuld

Rente dekkingsratio	-16x
Contant	CN¥1.04b
Aandelen	CN¥3.39b
Totaal verplichtingen	CN¥1.43b
Totaal activa	CN¥4.82b

Recente financiële gezondheidsupdates

Is LifeTech Scientific (HKG:1302) A Risky Investment?

Nov 20

LifeTech Scientific (HKG:1302) Could Easily Take On More Debt

Mar 31

Recent updates

LifeTech Scientific Corporation (HKG:1302) Looks Just Right With A 29% Price Jump

Oct 02

Some Confidence Is Lacking In LifeTech Scientific Corporation's (HKG:1302) P/E

Jul 05

LifeTech Scientific's (HKG:1302) Soft Earnings Are Actually Better Than They Appear

Apr 25

What LifeTech Scientific Corporation's (HKG:1302) P/E Is Not Telling You

Dec 25

Returns On Capital At LifeTech Scientific (HKG:1302) Have Stalled

Nov 28

At HK$2.37, Is LifeTech Scientific Corporation (HKG:1302) Worth Looking At Closely?

Nov 03

Here's What To Make Of LifeTech Scientific's (HKG:1302) Decelerating Rates Of Return

Oct 14

There's Been No Shortage Of Growth Recently For LifeTech Scientific's (HKG:1302) Returns On Capital

Jul 15

Does LifeTech Scientific (HKG:1302) Deserve A Spot On Your Watchlist?

Jun 30

A Look At The Fair Value Of LifeTech Scientific Corporation (HKG:1302)

Jun 15

Returns At LifeTech Scientific (HKG:1302) Are On The Way Up

Apr 03

Here's Why I Think LifeTech Scientific (HKG:1302) Is An Interesting Stock

Mar 15

Is LifeTech Scientific Corporation (HKG:1302) Potentially Undervalued?

Jan 22

Some Investors May Be Worried About LifeTech Scientific's (HKG:1302) Returns On Capital

Dec 19

Here's Why I Think LifeTech Scientific (HKG:1302) Might Deserve Your Attention Today

Dec 06

Is LifeTech Scientific (HKG:1302) A Risky Investment?

Nov 20

An Intrinsic Calculation For LifeTech Scientific Corporation (HKG:1302) Suggests It's 34% Undervalued

Oct 12

The Returns On Capital At LifeTech Scientific (HKG:1302) Don't Inspire Confidence

Sep 13

Should You Be Adding LifeTech Scientific (HKG:1302) To Your Watchlist Today?

Aug 28

What Is LifeTech Scientific Corporation's (HKG:1302) Share Price Doing?

Aug 13

LifeTech Scientific's (HKG:1302) Returns On Capital Not Reflecting Well On The Business

Jun 08

Here's Why I Think LifeTech Scientific (HKG:1302) Is An Interesting Stock

May 26

Should You Investigate LifeTech Scientific Corporation (HKG:1302) At HK$4.14?

May 11

LifeTech Scientific (HKG:1302) Could Easily Take On More Debt

Mar 31

Shareholders Are Thrilled That The LifeTech Scientific (HKG:1302) Share Price Increased 274%

Feb 21

Do Insiders Own Lots Of Shares In LifeTech Scientific Corporation (HKG:1302)?

Jan 26

Does LifeTech Scientific's (HKG:1302) Statutory Profit Adequately Reflect Its Underlying Profit?

Dec 13

Are Strong Financial Prospects The Force That Is Driving The Momentum In LifeTech Scientific Corporation's HKG:1302) Stock?

Nov 25

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( CN¥2.2B ) 1302 } overtreffen de korte termijn passiva ( CN¥826.5M ).

Langlopende schulden: De kortetermijnactiva 1302 ( CN¥2.2B ) overtreffen de langetermijnschulden ( CN¥602.8M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: 1302 heeft meer geld in kas dan de totale schuld.

Schuld verminderen: De schuld/eigen vermogen-ratio van 1302 is de afgelopen 5 jaar gedaald van 22.7% naar 2.9%.

Schuldendekking: De schuld van 1302 wordt goed gedekt door de operationele kasstroom ( 300.6% ).

Rentedekking: 1302 verdient meer rente dan het betaalt, dus de dekking van rentebetalingen is geen probleem.

LifeTech Scientific Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Is LifeTech Scientific (HKG:1302) A Risky Investment?

LifeTech Scientific (HKG:1302) Could Easily Take On More Debt

Recent updates

Investor sentiment improves as stock rises 32%

Investor sentiment deteriorates as stock falls 20%

LifeTech Scientific Corporation (HKG:1302) Looks Just Right With A 29% Price Jump

Investor sentiment improves as stock rises 18%

First half 2024 earnings released: EPS: CN¥0.046 (vs CN¥0.049 in 1H 2023)

New minor risk - Profit margin trend

LifeTech Scientific Corporation to Report First Half, 2024 Results on Aug 30, 2024

Some Confidence Is Lacking In LifeTech Scientific Corporation's (HKG:1302) P/E

LifeTech Scientific Corporation Announces One-Year Follow-Up Results of Phase II Clinical Study of IBS Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System

LifeTech Scientific's (HKG:1302) Soft Earnings Are Actually Better Than They Appear

LifeTech Scientific Corporation, Annual General Meeting, May 27, 2024

Full year 2023 earnings released: EPS: CN¥0.06 (vs CN¥0.077 in FY 2022)

LifeTech Scientific Corporation to Report Fiscal Year 2023 Results on Mar 28, 2024

What LifeTech Scientific Corporation's (HKG:1302) P/E Is Not Telling You

Returns On Capital At LifeTech Scientific (HKG:1302) Have Stalled

At HK$2.37, Is LifeTech Scientific Corporation (HKG:1302) Worth Looking At Closely?

First half 2023 earnings released: EPS: CN¥0.049 (vs CN¥0.05 in 1H 2022)

Epione Surgical Navigation System Obtained Official Registration Approval by the China NMPA

Investors Met With Slowing Returns on Capital At LifeTech Scientific (HKG:1302)

LifeTech Scientific Corporation to Report First Half, 2023 Results on Aug 30, 2023

Is There Now An Opportunity In LifeTech Scientific Corporation (HKG:1302)?

Lifetech Scientific Corporation Announces Enrollment in the Phase Iii Clinical Study of Ibs®? Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System Completed

Investors Met With Slowing Returns on Capital At LifeTech Scientific (HKG:1302)

Full year 2022 earnings released: EPS: CN¥0.077 (vs CN¥0.068 in FY 2021)

Investor sentiment improved over the past week

LifeTech Scientific Corporation Announces Enrollment in the China Randomized Controlled Clinical Study of IBS Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System Completed

Insufficient new directors

Here's What To Make Of LifeTech Scientific's (HKG:1302) Decelerating Rates Of Return

LifeTech Scientific Corporation Announces FDA Approval Investigator-Initiated Pre-Market Clinical Trial of Lambre Plus Laa Closure System Obtained Medical Insurance Coverage in the US

First half 2022 earnings released: EPS: CN¥0.05 (vs CN¥0.047 in 1H 2021)

LifeTech Scientific Corporation to Report Q2, 2022 Results on Aug 30, 2022

There's Been No Shortage Of Growth Recently For LifeTech Scientific's (HKG:1302) Returns On Capital

Does LifeTech Scientific (HKG:1302) Deserve A Spot On Your Watchlist?

A Look At The Fair Value Of LifeTech Scientific Corporation (HKG:1302)

Insufficient new directors

Returns At LifeTech Scientific (HKG:1302) Are On The Way Up

Full year 2021 earnings: EPS and revenues miss analyst expectations

LifeTech Scientific Corporation, Annual General Meeting, May 27, 2022

Here's Why I Think LifeTech Scientific (HKG:1302) Is An Interesting Stock

Is LifeTech Scientific Corporation (HKG:1302) Potentially Undervalued?

Some Investors May Be Worried About LifeTech Scientific's (HKG:1302) Returns On Capital

Here's Why I Think LifeTech Scientific (HKG:1302) Might Deserve Your Attention Today

Lifetech Scientific Corporation Announces YuranosTM Abdominal Aortic Stent Graft System Obtained Registration Approval from the China NMPA

Is LifeTech Scientific (HKG:1302) A Risky Investment?

An Intrinsic Calculation For LifeTech Scientific Corporation (HKG:1302) Suggests It's 34% Undervalued

The Returns On Capital At LifeTech Scientific (HKG:1302) Don't Inspire Confidence

First half 2021 earnings released: EPS CN¥0.047 (vs CN¥0.023 in 1H 2020)

Should You Be Adding LifeTech Scientific (HKG:1302) To Your Watchlist Today?

What Is LifeTech Scientific Corporation's (HKG:1302) Share Price Doing?

Investor sentiment deteriorated over the past week

LifeTech Scientific Corporation Announces Grant of Medical Device Registration Certificate in Malaysia for Its Self-Developed Ibs Angeltm Iron Bioresorbable Scaffold System

LifeTech Scientific's (HKG:1302) Returns On Capital Not Reflecting Well On The Business

Here's Why I Think LifeTech Scientific (HKG:1302) Is An Interesting Stock

Should You Investigate LifeTech Scientific Corporation (HKG:1302) At HK$4.14?

Investor sentiment improved over the past week

Non-Executive Director has left the company

Full year 2020 earnings released: EPS CN¥0.05 (vs CN¥0.031 in FY 2019)

LifeTech Scientific (HKG:1302) Could Easily Take On More Debt

Full year 2020 earnings released: EPS CN¥0.05 (vs CN¥0.031 in FY 2019)

LifeTech Scientific Corporation to Report Fiscal Year 2020 Results on Mar 30, 2021

New 90-day low: HK$3.62

Shareholders Are Thrilled That The LifeTech Scientific (HKG:1302) Share Price Increased 274%

Lifetech Scientific Corporation Announces Admission to Special Examination and Approval Procedure for Innovative Medical Devices in Respect of Artery Stent Graft System

Do Insiders Own Lots Of Shares In LifeTech Scientific Corporation (HKG:1302)?

New 90-day high: HK$5.46

New 90-day high: HK$4.43

Does LifeTech Scientific's (HKG:1302) Statutory Profit Adequately Reflect Its Underlying Profit?

Are Strong Financial Prospects The Force That Is Driving The Momentum In LifeTech Scientific Corporation's HKG:1302) Stock?

Gl Trade Investment III L.P. and Gao Ling Fund, L.P., a fund managed by Hillhouse Capital Management, Ltd. acquired 10.67% stake in LifeTech Scientific Corporation (SEHK:1302) from Central Huijin Investment Ltd.

Market bids up stock over the past week

New 90-day high: HK$2.99

Market bids up stock over the past week

New 90-day low: HK$2.05